In only six weeks Twist identified monoclonal antibodies to form basis of Covid-19 therapies

Allie Nawrat 6 May 2020 (Last Updated May 6th, 2020 14:42)

Twist Bioscience has discovered competitive monoclonal antibodies against SARS-CoV-2, the virus that causes Covid-19, which could be used to develop therapeutic candidates and diagnostic tools.

The monoclonal antibodies discovered bind with a high affinity to the receptor binding domain on SARS-CoV-2's spike protein, which has been shown to be central to the virus infecting human cells. Others bind to the human ACE2 cellular receptor, which is the binding site of the virus in the human body.

Twist CEO and co-founder Emily Leproust noted: “The rapid emergence of a global pandemic requires agile countermeasures bringing together the best science to defeat COVID-19, and we deployed our biopharma activities to meet this challenge.

“By leveraging our unique capability to precisely write DNA along with our fully human antibody libraries derived from natural human antibodies, we found leads against antigens involved in SARS-CoV-2 infection.

"We generated highly potent and functional monoclonal antibodies against COVID-19 in a matter of just six weeks.”